GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

2 Oct 2009 15:20

RNS Number : 1752A
Omega Diagnostics Group PLC
02 October 2009
 



Financial Services Authority

TR-1:NOTIFICATION OF MAJOR INTEREST IN SHARES

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: 

Omega Diagnostics Group Plc

2. Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

Yes

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: 

Legal & General Group Plc (Group)

Legal & General Investment Management Limited (LGIM)

Legal & General Group Plc (L&G)

4. Full name of shareholder(s)  (if different from 3.):

Legal & General Assurance Society Limited (LGAS & LGPL)

5. Date of the transaction and date on which the threshold is crossed or reached: 

28 September 2009

(30 September 2009)

6. Date on which issuer notified:

01 October 2009

7. Threshold(s) that is/are crossed or reached: 

Above 5% (Group)

Above 5% (LGIM)

Above 3% (L&G)

  

8. Notified details:

A: Voting rights attached to shares 

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights

Direct

Indirect

Direct

Indirect

ORD

GBP 0.04

Below 3%

(L&G)

2,060,000

2,060,000

9.98

Below 5%

(LGIM)

First notification under DTR Sourcebook

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date

Exercise/  Conversion Period

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments 

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date 

Exercise/ Conversion period 

Number of voting rights instrument refers to

% of voting rights 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,060,000

9.98

  

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable:

Legal & General Group Plc (Direct and Indirect) (Group) (2,060,000 - 9.98 % = Total Position) 

Legal & General Investment Management (Holdings) Limited (LGIMH) (Direct and Indirect) (2,060,000 - 9.98 % = Total Position)

Legal & General Investment Management Limited (Indirect) (LGIM) (2,060,000 - 9.98 % = Total Position)

Legal & General Group Plc (Direct) (L&G) (2,060,000 - 9.98 % = LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) 

Legal & General Insurance Holdings Limited (Direct) (LGIH) (1,648,000 - 7.98 % = LGAS & LGPL)

Legal & General Assurance (Pensions Management) Limited (PMC) 

Legal & General Assurance Society Limited (LGAS & LGPL) (1,648,000 - 7.98 % = LGAS & LGPL)

Legal & General Pensions Limited (Direct)  (LGPL)

Proxy Voting:

10. Name of the proxy holder:

N/A

11. Number of voting rights proxy holder will cease to hold:

N/A

12. Date on which proxy holder will cease to hold voting rights:

N/A

13. Additional information:

Notification using the total voting rights figure of 20,632,907

14. Contact name:

Helen Lewis (LGIM)

15. Contact telephone number:

020 3124 3851

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLUUASRKWRRRAA
Date   Source Headline
22nd Oct 20197:00 amRNSTrading Update and Notice of Interim Results
15th Oct 20192:29 pmRNSHolding(s) in Company
14th Oct 20198:18 amRNSHolding(s) in Company
14th Oct 20197:00 amRNSHolding(s) in Company
11th Oct 20198:00 amRNSHolding(s) in Company
10th Oct 201910:30 amRNSResult of General Meeting
27th Sep 201910:00 amRNSNotice of AGM and posting of annual report
23rd Sep 20197:01 amRNSPlacing & Subscription, Notice of General Meeting
23rd Sep 20197:00 amRNSFinal Results
16th Sep 20197:00 amRNSUpdate on VISITECT® CD4 Advanced Disease
10th Sep 20197:00 amRNSPurchase Order for Chinese Food Detective® test
20th Aug 20197:00 amRNSFirst VISITECT® CD4 Advanced Disease Test Order
16th Aug 201911:00 amRNSRe. Results, Trading Update & Nigerian CD4 Order
8th Aug 20197:00 amRNSInvestor Briefing
6th Jun 20197:00 amRNSAnnouncement of Results
5th Jun 20191:37 pmRNSHolding(s) in Company
3rd Jun 20191:43 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription to raise c.£635,000
17th Apr 20197:00 amRNSTrading Update
18th Mar 20197:00 amRNSCE-Mark for VISITECT® CD4 Advanced Disease test
6th Mar 20197:00 amRNSVISITECT® CD4 update
1st Mar 20197:00 amRNSBoard Appointment
29th Jan 20197:00 amRNSVISITECT® CD4 Advanced Disease test update
10th Dec 20189:00 amRNSDirectorate Change
3rd Dec 20187:00 amRNSInterim results
19th Oct 20184:27 pmRNSHolding(s) in Company
10th Oct 20187:00 amRNSTrading Update and Notice of Interim Results
8th Oct 20182:38 pmRNSHolding(s) in Company
27th Sep 20187:00 amRNSAllergy CE-Mark and first Purchase Order
14th Sep 201811:25 amRNSResult of AGM
10th Sep 20188:56 amRNSHolding(s) in Company
6th Aug 20187:01 amRNSFinal Results
6th Aug 20187:00 amRNSVISITECT® CD4 Advanced Disease Development Update
30th Jul 20185:29 pmRNSHolding(s) in Company
18th Jul 20187:00 amRNSVISITECT® CD4 commercialisation update
12th Jul 20187:00 amRNSInvestor results presentation
2nd Jul 20187:00 amRNSNotice of Results
28th Jun 20187:00 amRNSDisposal of infectious disease business
21st May 20187:00 amRNSVISITECT CD4 development update
8th May 20187:00 amRNSAllersys? CE-Mark
2nd May 20187:41 amRNSClosure of Omega Diagnostics GmbH
24th Apr 20185:04 pmRNSPDMR Dealing
24th Apr 20187:00 amRNSHolding(s) in Company
23rd Apr 20183:50 pmRNSHolding(s) in Company
23rd Apr 20182:24 pmRNSDirector/PDMR Shareholding
23rd Apr 20182:22 pmRNSHolding(s) in Company
23rd Apr 20189:31 amRNSDirector/PDMR Shareholding
20th Apr 20187:00 amRNSAllersys Distribution Agreement
19th Apr 201811:45 amRNSInvestor Evening
10th Apr 20184:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.